Zacks: Analysts Expect Seres Therapeutics Inc (MCRB) to Post -$0.74 EPS

Wall Street brokerages forecast that Seres Therapeutics Inc (NASDAQ:MCRB) will post earnings per share of ($0.74) for the current quarter, according to Zacks. Two analysts have made estimates for Seres Therapeutics’ earnings. The highest EPS estimate is ($0.70) and the lowest is ($0.77). Seres Therapeutics posted earnings per share of ($0.63) in the same quarter last year, which suggests a negative year-over-year growth rate of 17.5%. The company is scheduled to announce its next quarterly earnings results on Thursday, May 3rd.

On average, analysts expect that Seres Therapeutics will report full-year earnings of ($2.64) per share for the current fiscal year, with EPS estimates ranging from ($2.90) to ($2.37). For the next financial year, analysts expect that the firm will report earnings of ($2.68) per share, with EPS estimates ranging from ($3.56) to ($2.04). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Seres Therapeutics.

How to Become a New Pot Stock Millionaire

Seres Therapeutics (NASDAQ:MCRB) last posted its earnings results on Thursday, March 8th. The biotechnology company reported ($0.71) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.73) by $0.02. Seres Therapeutics had a negative net margin of 278.44% and a negative return on equity of 103.46%. The firm had revenue of $3.06 million during the quarter, compared to the consensus estimate of $3.00 million.

MCRB has been the subject of several research reports. Zacks Investment Research downgraded shares of Seres Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. BidaskClub downgraded shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, February 7th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $18.00.

Seres Therapeutics stock traded down $0.26 during trading on Tuesday, hitting $7.64. The company had a trading volume of 168,951 shares, compared to its average volume of 142,336. The company has a market capitalization of $321.12, a PE ratio of -3.46 and a beta of 0.51. The company has a debt-to-equity ratio of 0.15, a quick ratio of 4.90 and a current ratio of 4.90. Seres Therapeutics has a 1-year low of $6.65 and a 1-year high of $17.42.

Several large investors have recently bought and sold shares of the business. Millennium Management LLC grew its stake in shares of Seres Therapeutics by 40.3% in the fourth quarter. Millennium Management LLC now owns 295,675 shares of the biotechnology company’s stock worth $2,998,000 after acquiring an additional 84,936 shares in the last quarter. Two Sigma Investments LP grew its stake in shares of Seres Therapeutics by 243.3% in the fourth quarter. Two Sigma Investments LP now owns 38,445 shares of the biotechnology company’s stock worth $390,000 after acquiring an additional 27,245 shares in the last quarter. Two Sigma Advisers LP lifted its position in shares of Seres Therapeutics by 153.6% during the 4th quarter. Two Sigma Advisers LP now owns 35,500 shares of the biotechnology company’s stock worth $360,000 after purchasing an additional 21,500 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Seres Therapeutics by 72.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 49,530 shares of the biotechnology company’s stock worth $502,000 after purchasing an additional 20,839 shares during the last quarter. Finally, Deutsche Bank AG lifted its position in shares of Seres Therapeutics by 146.1% during the 4th quarter. Deutsche Bank AG now owns 227,190 shares of the biotechnology company’s stock worth $2,302,000 after purchasing an additional 134,874 shares during the last quarter. Institutional investors and hedge funds own 79.02% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Zacks: Analysts Expect Seres Therapeutics Inc (MCRB) to Post -$0.74 EPS” was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another site, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this story can be read at https://ledgergazette.com/2018/04/23/zacks-analysts-expect-seres-therapeutics-inc-mcrb-to-post-0-74-eps.html.

About Seres Therapeutics

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Get a free copy of the Zacks research report on Seres Therapeutics (MCRB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply